This company is no longer active
IMRA Stock Overview
IMARA Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapeutics to treat patients suffering from serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
IMARA Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.32 |
| 52 Week High | US$6.32 |
| 52 Week Low | US$0.97 |
| Beta | 1.08 |
| 1 Month Change | 50.48% |
| 3 Month Change | 43.64% |
| 1 Year Change | 321.33% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -57.87% |
Recent News & Updates
Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal
Oct 13Imara: Potential Liquidation
Sep 29Recent updates
Cancer drug developer Enliven Therapeutics and Imara to merge in all-stock deal
Oct 13Imara: Potential Liquidation
Sep 29We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Jul 23
We're Keeping An Eye On IMARA's (NASDAQ:IMRA) Cash Burn Rate
Sep 09IMARA (IMRA) EHA Investor Presentations - Slideshow
Jun 18Is IMARA (NASDAQ:IMRA) In A Good Position To Invest In Growth?
May 03Companies Like IMARA (NASDAQ:IMRA) Are In A Position To Invest In Growth
Jan 11Imara's sickle cell treatment shows promising action in mid-stage study
Jan 06Imara EPS in-line
Nov 05Shareholder Returns
| IMRA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 20.2% | 3.7% | -2.2% |
| 1Y | 321.3% | -0.7% | 18.3% |
Return vs Industry: IMRA exceeded the US Pharmaceuticals industry which returned 8.5% over the past year.
Return vs Market: IMRA exceeded the US Market which returned -9% over the past year.
Price Volatility
| IMRA volatility | |
|---|---|
| IMRA Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMRA's share price has been volatile over the past 3 months.
Volatility Over Time: IMRA's weekly volatility has decreased from 17% to 9% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 6 | Rahul Ballal | imaratx.com |
IMARA Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapeutics to treat patients suffering from serious diseases. The company was incorporated in 2016 and is based in Brookline, Massachusetts.
IMARA Inc. Fundamentals Summary
| IMRA fundamental statistics | |
|---|---|
| Market cap | US$165.80m |
| Earnings (TTM) | US$1.49m |
| Revenue (TTM) | n/a |
111.4x
P/E Ratio0.0x
P/S RatioIs IMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMRA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$1.49m |
| Earnings | US$1.49m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.057 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did IMRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/24 08:00 |
| End of Day Share Price | 2023/02/23 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
IMARA Inc. is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Edward White | H.C. Wainwright & Co. |
| Joseph Schwartz | Leerink Partners LLC |